1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Phage Therapy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Phage Therapy Market, by Therapy Type
8.1.1. Monophage Therapy
8.1.1.1. Market Revenue and Forecast
8.1.2. Phage Cocktail
8.1.2.1. Market Revenue and Forecast
8.1.3. Engineered/Synthetic Phages
8.1.3.1. Market Revenue and Forecast
8.1.4. Other Phage-based Modalities (e.g., Phage Lysins, Endolysins)
8.1.4.1. Market Revenue and Forecast
9.1. Phage Therapy Market, by Application
9.1.1. Infectious Disease Treatment (Human Health)
9.1.1.1. Market Revenue and Forecast
9.1.2. Veterinary Applications
9.1.2.1. Market Revenue and Forecast
9.1.3. Food Safety & Agriculture
9.1.3.1. Market Revenue and Forecast
9.1.4. Environmental Applications (Wastewater, Bioremediation, etc.)
9.1.4.1. Market Revenue and Forecast
9.1.5. Other Applications (Microbiome Modulation, Diagnostics, etc.)
9.1.5.1. Market Revenue and Forecast
10.1. Phage Therapy Market, by Route of Administration
10.1.1. Oral
10.1.1.1. Market Revenue and Forecast
10.1.2. Topical
10.1.2.1. Market Revenue and Forecast
10.1.3. Injectable
10.1.3.1. Market Revenue and Forecast
10.1.4. Other Routes (Inhalation, Nasal, etc.)
10.1.4.1. Market Revenue and Forecast
11.1. Phage Therapy Market, by End-User
11.1.1. Hospitals & Specialty Clinics
11.1.1.1. Market Revenue and Forecast
11.1.2. Research Institutes & Academic Centers
11.1.2.1. Market Revenue and Forecast
11.1.3. Veterinary Clinics & Animal Health Providers
11.1.3.1. Market Revenue and Forecast
11.1.4. Other End-Users (Food Safety Agencies, Environmental Bodies, etc.)
11.1.4.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Therapy Type
12.1.2. Market Revenue and Forecast, by Application
12.1.3. Market Revenue and Forecast, by Route of Administration
12.1.4. Market Revenue and Forecast, by End-User
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Therapy Type
12.1.5.2. Market Revenue and Forecast, by Application
12.1.5.3. Market Revenue and Forecast, by Route of Administration
12.1.5.4. Market Revenue and Forecast, by End-User
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Therapy Type
12.1.6.2. Market Revenue and Forecast, by Application
12.1.6.3. Market Revenue and Forecast, by Route of Administration
12.1.6.4. Market Revenue and Forecast, by End-User
12.2. Europe
12.2.1. Market Revenue and Forecast, by Therapy Type
12.2.2. Market Revenue and Forecast, by Application
12.2.3. Market Revenue and Forecast, by Route of Administration
12.2.4. Market Revenue and Forecast, by End-User
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Therapy Type
12.2.5.2. Market Revenue and Forecast, by Application
12.2.5.3. Market Revenue and Forecast, by Route of Administration
12.2.5.4. Market Revenue and Forecast, by End-User
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Therapy Type
12.2.6.2. Market Revenue and Forecast, by Application
12.2.6.3. Market Revenue and Forecast, by Route of Administration
12.2.6.4. Market Revenue and Forecast, by End-User
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Therapy Type
12.2.7.2. Market Revenue and Forecast, by Application
12.2.7.3. Market Revenue and Forecast, by Route of Administration
12.2.7.4. Market Revenue and Forecast, by End-User
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Therapy Type
12.2.8.2. Market Revenue and Forecast, by Application
12.2.8.3. Market Revenue and Forecast, by Route of Administration
12.2.8.4. Market Revenue and Forecast, by End-User
12.3. APAC
12.3.1. Market Revenue and Forecast, by Therapy Type
12.3.2. Market Revenue and Forecast, by Application
12.3.3. Market Revenue and Forecast, by Route of Administration
12.3.4. Market Revenue and Forecast, by End-User
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Therapy Type
12.3.5.2. Market Revenue and Forecast, by Application
12.3.5.3. Market Revenue and Forecast, by Route of Administration
12.3.5.4. Market Revenue and Forecast, by End-User
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Therapy Type
12.3.6.2. Market Revenue and Forecast, by Application
12.3.6.3. Market Revenue and Forecast, by Route of Administration
12.3.6.4. Market Revenue and Forecast, by End-User
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Therapy Type
12.3.7.2. Market Revenue and Forecast, by Application
12.3.7.3. Market Revenue and Forecast, by Route of Administration
12.3.7.4. Market Revenue and Forecast, by End-User
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Therapy Type
12.3.8.2. Market Revenue and Forecast, by Application
12.3.8.3. Market Revenue and Forecast, by Route of Administration
12.3.8.4. Market Revenue and Forecast, by End-User
12.4. MEA
12.4.1. Market Revenue and Forecast, by Therapy Type
12.4.2. Market Revenue and Forecast, by Application
12.4.3. Market Revenue and Forecast, by Route of Administration
12.4.4. Market Revenue and Forecast, by End-User
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Therapy Type
12.4.5.2. Market Revenue and Forecast, by Application
12.4.5.3. Market Revenue and Forecast, by Route of Administration
12.4.5.4. Market Revenue and Forecast, by End-User
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Therapy Type
12.4.6.2. Market Revenue and Forecast, by Application
12.4.6.3. Market Revenue and Forecast, by Route of Administration
12.4.6.4. Market Revenue and Forecast, by End-User
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Therapy Type
12.4.7.2. Market Revenue and Forecast, by Application
12.4.7.3. Market Revenue and Forecast, by Route of Administration
12.4.7.4. Market Revenue and Forecast, by End-User
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Therapy Type
12.4.8.2. Market Revenue and Forecast, by Application
12.4.8.3. Market Revenue and Forecast, by Route of Administration
12.4.8.4. Market Revenue and Forecast, by End-User
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Therapy Type
12.5.2. Market Revenue and Forecast, by Application
12.5.3. Market Revenue and Forecast, by Route of Administration
12.5.4. Market Revenue and Forecast, by End-User
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Therapy Type
12.5.5.2. Market Revenue and Forecast, by Application
12.5.5.3. Market Revenue and Forecast, by Route of Administration
12.5.5.4. Market Revenue and Forecast, by End-User
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Therapy Type
12.5.6.2. Market Revenue and Forecast, by Application
12.5.6.3. Market Revenue and Forecast, by Route of Administration
12.5.6.4. Market Revenue and Forecast, by End-User
13.1. Micreos B.V.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Eliava Biopreparations Ltd. (Eliava Institute, Georgia)
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. PhagePro Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. EnBiotix, Inc. (Merged with Armata Pharmaceuticals)
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Technophage SA
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Fixed-Phage Ltd.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. iNtODEWORLD (South Korea)
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Proteon Pharmaceuticals S.A.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Phagelux Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. AmpliPhi Biosciences
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client